Drug Discovery
ByDid NVIDIA Become the Central AI Catalyst for Biopharma in 2025—And Which Players Benefited Most?
2025 marked a pivotal year for artificial intelligence in biopharma. As life sciences companies moved beyond isolated AI…
Which AI Biopharma Startups Truly Won in 2025—And How Did NVIDIA, Big Pharma Collaborations, and Deal Value Define Success?
Executive Perspective 2025 marked a decisive shift for AI biopharma startups—from experimental promise to measurable strategic impact. Success…
Is Nabla Bio Redefining AI-Driven Protein Engineering as Pharma Seeks Faster Paths to Biologics Innovation?
Executive Summary Nabla Bio is emerging as a next-generation AI biotech focused on computationally driven protein and antibody…
Is AbCellera Biologics Building a Durable AI Antibody Discovery Engine as Pharma Partnerships Signal Multi-Billion-Dollar Potential?
Executive Summary AbCellera Biologics has established itself as a global leader in AI-driven antibody discovery, combining advanced computational…
Does the U.S. Exit from WHO Redefine Global Health Governance? Washington Completes Historic Withdrawal
23 January 2026 Executive Summary The United States has formally completed its withdrawal from the World Health Organization…
Is Partnership-Led Innovation Replacing M&A in Oncology? BMS and Janux Strike $850 Million T-Cell Engager Deal
January 2026 Executive Summary Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Janux Therapeutics, a…
